$38.25
0.13% today
Nasdaq, Nov 07, 10:00 pm CET
ISIN
CA98420N1050
Symbol
XENE

Xenon Pharmaceuticals Inc. Stock price

$38.30
-1.25 3.16% 1M
+3.12 8.87% 6M
-0.90 2.30% YTD
-6.64 14.78% 1Y
+3.53 10.15% 3Y
+27.33 249.13% 5Y
+30.31 379.35% 10Y
+27.80 264.76% 20Y
Nasdaq, Closing price Thu, Nov 06 2025
-0.36 0.93%
ISIN
CA98420N1050
Symbol
XENE
Industry

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$487.6m
Shares outstanding
76.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
94.6%
Return on Equity
-31.0%
ROCE
-49.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$7.5m | $7.7m
EBITDA
$-315.5m | $-366.4m
EBIT
$-318.1m | $-367.6m
Net Income
$-278.2m | $-333.3m
Free Cash Flow
$-233.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-35.0% | -32.4%
EBIT
-33.9% | -31.6%
Net Income
-39.8% | -42.2%
Free Cash Flow
-48.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-4,207.0% | -4,770.5%
EBIT
-4,241.6%
Net
-3,709.7% | -4,339.7%
Free Cash Flow
-3,106.5%
More
EPS
$-3.5
FCF per Share
$-3.0
Short interest
8.9%
Employees
322
Rev per Employee
$0.0
Show more

Is Xenon Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Xenon Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Xenon Pharmaceuticals Inc. forecast:

25x Buy
96%
1x Hold
4%

Analyst Opinions

26 Analysts have issued a Xenon Pharmaceuticals Inc. forecast:

Buy
96%
Hold
4%

Financial data from Xenon Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
7.50 7.50
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 73 73
22% 22%
973%
- Research and Development Expense 253 253
42% 42%
3,368%
-316 -316
35% 35%
-4,207%
- Depreciation and Amortization 2.59 2.59
33% 33%
35%
EBIT (Operating Income) EBIT -318 -318
34% 34%
-4,242%
Net Profit -278 -278
40% 40%
-3,710%

In millions USD.

Don't miss a Thing! We will send you all news about Xenon Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xenon Pharmaceuticals Inc. Stock News

Neutral
GlobeNewsWire
one day ago
VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences. Stifel 2025 Healthcare ...
Neutral
Seeking Alpha
4 days ago
Xenon Pharmaceuticals Inc. ( XENE ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Colleen Alabiso Ian Mortimer - President, CEO, Principal Accounting Officer & Director Christopher Kenney - Chief Medical Officer Thomas Kelly - Chief Financial Officer Darren Cline - Chief Commercial Officer and Member of Executive Team Conference Call Participants Paul Matteis - Stifel,...
Neutral
GlobeNewsWire
4 days ago
– Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete  – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to recruit – Phase 1 Nav1.7 & Kv7 studies underway – Tucker Kelly appointed as Chief Financial Officer, bringing extensive strategic commercial finance experience in anticipation of the azetukalner launch – ...
More Xenon Pharmaceuticals Inc. News

Company Profile

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Head office Canada
CEO Ian Mortimer
Employees 322
Founded 1996
Website www.xenon-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today